Alaunos Therapeutics, Inc. · NASDAQ:TCRT

Alaunos Therapeutics — Ziopharm Oncology — Technical Presentation (May 2014)

10 slides from Alaunos Therapeutics's technical presentation, May 22, 2014

  1. Slide 1: Inducible Gene Regulation: RheoSwitch Therapeutic System

    1. The Switch Components : The RTS® gene program includes receptor protein fusions: VP16-RXR and Gal4-EcR. They form unstable and unproductive heterodimers in the absence of any ligand. 2. The Inducible Promoter : A customizable promoter to which basal transcription proteins are recruited and the ta

  2. Slide 2: IL-12 Production is Modulated by Activator Ligand in HT 1080 Cells

    IL-12 Production is Modulated by Activator Ligand in HT 1080 Cells On Off On AL=75nM

  3. Slide 3: Dose-Dependent Increase in Expression of Tumor IL-12 mRNA & IL-12 Protein in Response to Veledimex

    Dose-Dependent Increase in Expression of Tumor IL-12 mRNA & IL-12 Protein in Response to Veledimex RTS gDNA Tumor Veledimex Level Time (days) Time (days) Vehicle/Vehicle Vehicle/Veledimex mg/m Ad (1e10) + Veledimex 15 mg/m Ad (1e10) + Veledimex 30 mg/m Ad (1e10) + Veledimex 75 mg/m Ad (1e10) + Veled

  4. Slide 4: Veledimex Increases Tumor CD8+ & CD4+ While Decreasing CD4+ Fox P3+ TILs in the 4T1 Syngeneic Mouse

    Ad-RTS-mIL-12 + Veledimex Increases Tumor CD8 + & CD4 + While Decreasing CD4 + Fox P3 + TILs in the 4T1 Syngeneic Mouse Vehicle Ad-RTS-mIL-12 1 x 10 vp + Veledimex 150 mg/m CD8 + CD4 + CD4 + Fox P3 +

  5. Slide 5: Dose-Dependent Anti-Tumor Activity of Ad-RTS-mIL-12 + Veledimex (AL) in Murine 4T1 Model

    Dose-Dependent Anti-Tumor Activity of Ad-RTS- mIL-12 + Veledimex (AL) in Murine 4T1 Model Start of treatment Tumor volume reached 100-200 mm Vehicle/Vehicle Vehicle/Ad-RTS-mIL12 Vehicle/Veledimex mg/m Ad-RTS-mIL12 + AL mg/m Ad-RTS-mIL12 + AL mg/m Ad-RTS-mIL12 + AL mg/m Ad-RTS-mIL12 + AL 150mg/m Time

  6. Slide 6: Higher Veledimex Levels Normal and in GL261 Orthotopic Glioma Mouse Brains

    Higher Veledimex Levels Normal and in GL261 Orthotopic Glioma Mouse Brains Veledimex levels at 24 hr posttreatment 450 mg/m /day 1200 mg/m /day

  7. Slide 7: Effects of (AL) in the Orthotopic GL261 Mouse

    Effects of Ad-RTS-mIL-12 + Veledimex (AL) in the Orthotopic GL261 Mouse Normal Mouse Vehicle BID x 14 Ad-RTS-mIL-12 1x10 vp + AL mg/m /day BID x14 Treatment For 14 days Day 74 (end of study) Control Day 20

  8. Slide 8: Veledimex (in Chow) Results in Increased Survival in the GL261 Orthotopic Glioma Mouse Model

    Ad-RTS-mIL-12 + Veledimex (in Chow) Results in Increased Survival in the GL261 Orthotopic Glioma Mouse Model Veledimex administered ad lib in chow from Day 4 to EOS at ~ 675 mg/m /day Ad-RTS-mIL12 administered on Day 5 Vehicle/Vehicle Vehicle/AD (5e9) Vehicle/Activator chow (1000) Activator chow + A

  9. Slide 9: Veledimex (AL) Results in Increased Survival When Compared to Control in the GL261 Model

    Ad-RTS-mIL-12 + Veledimex (AL) Results in Increased Survival When Compared to Control in the GL261 Orthotopic Glioma Mouse Model Ad-RTS-mIL12 administered on Day ; Veledimex (mg/m ) administered BID for days from Day 5; maisine/saline maisine/vector Veledimex (AL)/saline AL 150/day + AD 1e10 AL 300/

  10. Slide 10: Veledimex significantly reduces brain cancer stem cells in GL-261 Orthotopic Glioma Model

    Ad-RTS-mIL-12 + veledimex significantly reduces brain cancer stem cells in GL-261 Orthotopic Glioma Model Nestin levels (marker for cancer stem cells) inverse correlation with survival (Pearson r= 0.92) Vehicle/Vehicle Vehicle/Ad-RTS-mIL-12 Vehicle/Veledimex Veledime x 450 mg/m /day Veledime x 600 m

Ziopharm Oncology — Technical Presentation (May 2014) on 6ix